EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m 2 Treated by Semaglutide: A 60‐Week Randomized Placebo‐Controlled Trial

Kelly C Allison iD, Thomas A Wadden iD, Kaitlyn DeRouen iD, Anastassia Amaro iD, Kayla G Collins iD, Anokha S Roy iD, Jena S Tronieri iD

International Journal of Eating Disorders · 15.11.2026

DOI: 10.1002/eat.70253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Eating Disorders, online erschienen am 15.11.2026. Verfasst von Kelly C Allison und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine disordered eating attitudes and behaviors in individuals treated with semaglutide 2.4 mg or placebo for 60 weeks.

Methods

Individuals seeking obesity treatment ( n = 120) randomized (3:2) to semaglutide or placebo, both with lifestyle intervention, were assessed at baseline and Weeks 20, 40, and 60. At each assessment, clinicians evaluated binge eating and eating disorder psychopathology (Eating Disorder Examination), and questionnaires measured loss of control (Loss of Control Over Eating Scale), drive for thinness [Eating Disorder Inventory (EDI)], body dissatisfaction (EDI and Body Satisfaction Scale), and mood (PHQ‐9). Following multiple imputation, ANCOVAs compared the groups in change at each assessment, controlling for baseline.

Results

Mean reductions from baseline in loss of control, global eating disorder pathology, weight and shape concern, drive for thinness, and body dissatisfaction were significantly greater with semaglutide compared to placebo at several timepoints. The groups did not differ significantly in binge frequency reductions. However, participants reporting baseline binge episodes ( n = 31) and those who had full or subthreshold binge‐eating disorder ( n = 18) were more likely to achieve abstinence with semaglutide compared to placebo. Reliable deteriorations in eating psychopathology, new onset of binge eating, and compensatory behaviors were rare, and symptom emergence did not seem higher with semaglutide.

Discussion

Semaglutide reduced eating disorder psychopathology and improved body image relative to placebo at 20 to 60 weeks of treatment for obesity management. Semaglutide also increased remission in those with binge eating. Disordered eating behaviors were rare but did occur, suggesting the need for periodic monitoring in at‐risk individuals. Trial Registration clinicaltrials.gov number NCT05548647

Schlagwörter

Stichwörter der Autor:innen

binge eatingdisordered eatingeating behaviorsglucagon‐like peptide receptor agonists (GLP‐1RAs)inappropriate compensatory behaviorsobesity management

Autor:innen und Institutionen

  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Psychology, East Carolina University, Greenville, North Carolina, USA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Kelly C Allison, Thomas A Wadden, Kaitlyn DeRouen, Anastassia Amaro, Kayla G Collins, Anokha S Roy, Jena S Tronieri

Förderung

  • Novo Nordisk

Zitieren

APA

Allison, K. C., Wadden, T. A., DeRouen, K., Amaro, A., Collins, K. G., Roy, A. S., & Tronieri, J. S. (2026). Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m 2 Treated by Semaglutide: A 60‐Week Randomized Placebo‐Controlled Trial. International Journal of Eating Disorders. https://doi.org/10.1002/eat.70253

Vancouver

Allison KC, Wadden TA, DeRouen K, Amaro A, Collins KG, Roy AS, et al. Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m 2 Treated by Semaglutide: A 60‐Week Randomized Placebo‐Controlled Trial. International Journal of Eating Disorders. 2026. doi:10.1002/eat.70253

BibTeX
@article{Allison2026,
  author = {Allison, Kelly C and Wadden, Thomas A and DeRouen, Kaitlyn and Amaro, Anastassia and Collins, Kayla G and Roy, Anokha S and Tronieri, Jena S},
  title = {Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m 2 Treated by Semaglutide: A 60‐Week Randomized Placebo‐Controlled Trial},
  journal = {International Journal of Eating Disorders},
  year = {2026},
  doi = {10.1002/eat.70253}
}
Kostenlos starten →